Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Interest & Investment Income (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Interest & Investment Income readings, the most recent being $984000.0 for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 18.74% to $984000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.4 million, a 31.29% increase, with the full-year FY2025 number at $4.4 million, up 31.37% from a year prior.
  • Interest & Investment Income hit $984000.0 in Q4 2025 for Avalo Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.2 million in Q4 2024 to a low of -$1.6 million in Q3 2023.
  • Median Interest & Investment Income over the past 5 years was -$111000.0 (2021), compared with a mean of -$115650.0.
  • Biggest five-year swings in Interest & Investment Income: plummeted 6976.47% in 2022 and later surged 1395.06% in 2024.
  • Avalo Therapeutics' Interest & Investment Income stood at -$1.2 million in 2021, then grew by 19.85% to -$949000.0 in 2022, then skyrocketed by 108.54% to $81000.0 in 2023, then surged by 1395.06% to $1.2 million in 2024, then decreased by 18.74% to $984000.0 in 2025.
  • The last three reported values for Interest & Investment Income were $984000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.